Medicx Fund Regulatory News (MXF)

Press Release

For immediate release

18 February 2015

MedicX Fund Limited

("MedicX Fund", "the Fund" or "the Company")

Issue of Equity

The Company announces that it has today issued 32,806,402 new Ordinary Shares of no par value ("New Shares") for cash at a price of 83.5 pence per share (the "Issue Price"), subject only to Admission, to Canaccord Genuity Limited, pursuant to the authorities granted by shareholders at the Company's annual general meeting held on 17 February 2015 (the "AGM"). Application has been made for the New Shares to be admitted to the premium segment of the Official List of the UK Listing Authority and to trading on the London Stock Exchange's main market for listed securities ("Admission"). It is expected that dealings in the New Shares will commence at 8.00 a.m. on 20 February 2015.

On Admission, the New Shares will be repurchased by the Company on market at the Issue Price pursuant to the shareholder authorities granted at the AGM, free of commission, to be held in treasury for later use by the Company to satisfy demand under the scrip dividend scheme and/or to be re-sold into the market to satisfy general market demand in an efficient and cost-effective manner. The net proceeds of any subsequent sales of shares out of treasury will be used in further pursuing the investment objective of the Company.

Enquiries:

MedicX Fund +44 (0) 1481 723 450

David Staples, Chairman

Octopus Healthcare Group +44 (0) 1483 869 500

Mike Adams, Chief Executive Officer

Mark Osmond, Chief Financial Officer

Canaccord Genuity Limited

Andrew Zychowski/Denis Flanagan +44 (0) 20 7523 8000

Buchanan Communications +44 (0) 20 7466 5000

Charles Ryland/Sophie McNulty

Information on MedicX Fund Limited

MedicX Fund Limited ("MXF", the "Fund" or the "Company", or together with its subsidiaries, the "Group") is a specialist primary care infrastructure investor in modern, purpose-built primary healthcare properties in the United Kingdom, listed on the London Stock Exchange, with a portfolio comprising 141 properties.

The Investment Adviser to the Company is Octopus Healthcare Adviser Ltd, which is authorised and regulated by the Financial Conduct Authority and is a subsidiary of the Octopus Healthcare Group. The Octopus Healthcare Group is a specialist investor, developer and manager of healthcare properties with 36 people operating across the UK.

The Company's website address is www.medicxfund.com. Neither the contents of the Company's website nor the contents of any website accessible from hyperlinks on the Company's website (or any other website) nor the contents off any website accessible from hyperlinks within this announcement, are incorporated into, or form part of, this announcement.